Drug intelligence / Profile preview

WSK-V102F

Development stage: Unknown
Lead developer: WestVac Biopharma
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

WSK-V102F is a recombinant protein subunit vaccine candidate developed by the West China Hospital of Sichuan University for the prevention of COVID-19. It is part of the WSK-V102 series of vaccines, which utilize recombinant technology to produce specific viral antigens, typically the SARS-CoV-2 spike protein, to elicit a protective immune response. WSK-V102F is being evaluated as a booster dose in adults who have previously received primary COVID-19 vaccinations. Clinical studies, such as the Phase 1 trial ChiCTR2400080850, focus on assessing the safety, immunogenicity, and protective efficacy of this vaccine variant against SARS-CoV-2.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on WSK-V102F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSK-V102F.

Explore the full profile